Rocuronium requirements on the Paediatric Intensive Care Unit: the value of monitoring neuromuscular function

ISRCTN ISRCTN71688724
DOI https://doi.org/10.1186/ISRCTN71688724
Protocol serial number N0045125254
Sponsor Department of Health
Funder Birmingham Children's Hospital NHS Trust (UK)
Submission date
30/09/2004
Registration date
30/09/2004
Last edited
13/09/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Oliver Bagshaw
Scientific

Birmingham Children's Hospital
Department of Anaesthesia
Steelhouse Lane
Birmingham
B4 6NH
United Kingdom

Study information

Primary study designInterventional
Study designRandomised controlled trial
Secondary study designRandomised controlled trial
Scientific title
Study objectivesDoes monitoring neuromuscular function on PICU (Paediatric Intensive Care Unit) have any advantages over standard practice of clinical assessment of neuromuscular function/drug requirements?
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedNervous System Diseases: Neuromuscular function
InterventionPatients randomly allocated to received either standard management of NMBD (neuromuscular blocking drug) administration or protocol driven according to monitored neuromuscular function.
Intervention typeOther
Primary outcome measure(s)

1. Total amount of NMBD administered
2. Speed of recovery or neuromuscular function once NMBDs stopped
3. Complications related to residual NM paralysis

Key secondary outcome measure(s)

Not provided at time of registration

Completion date31/05/2003

Eligibility

Participant type(s)Patient
Age groupChild
Upper age limit16 Years
SexNot Specified
Target sample size at registration30
Key inclusion criteria30 patients under the age of 16 years requiring administration of Rocuronium to facilitate mechanical ventilation for more than 48 hours.
Key exclusion criteriaNot provided at time of registration
Date of first enrolment01/06/2002
Date of final enrolment31/05/2003

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Birmingham Children's Hospital
Birmingham
B4 6NH
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan